Journal
JOURNAL OF CLINICAL MICROBIOLOGY
Volume 57, Issue 4, Pages -Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/JCM.01307-18
Keywords
CRISPR-Cas; diagnostics; infectious diseases; therapeutics
Categories
Funding
- National Institutes of Health (Clinical Center, Critical Care Medicine Department)
- National Institutes of Health (Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases)
Ask authors/readers for more resources
Infectious diseases remain a global threat contributing to excess morbidity and death annually, with the persistent potential for destabilizing pandemics. Improved understanding of the pathogenesis of bacteria, viruses, fungi, and parasites, along with rapid diagnosis and treatment of human infections, is essential for improving infectious disease outcomes worldwide. Genomic loci in bacteria and archaea, termed clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) proteins, function as an adaptive immune system for prokaryotes, protecting them against foreign invaders. CRISPR-Cas9 technology is now routinely applied for efficient gene editing, contributing to advances in biomedical science. In the past decade, improved understanding of other diverse CRISPR-Cas systems has expanded CRISPR applications, including in the field of infectious diseases. In this review, we summarize the biology of CRISPR-Cas systems and discuss existing and emerging applications to evaluate mechanisms of host-pathogen interactions, to develop accurate and portable diagnostic tests, and to advance the prevention and treatment of infectious diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available